BGLCBGLCIndustrials · Specialty Chemicals

BGLC Stock Forecast: BioNexus Gene Lab Corp. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.68
−7.36% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$2.0M
Ticker Nerd rank
16/ 100
Median analyst target
—
Analysts covering
—
Revenue$76K−96.6% y/y
Operating income−$312K
Net income−$286K
Free cash flow−$423K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.0%
1M
−44.6%
YTD
−82.8%
1Y
−85.8%
From 52W high
−85.8%
From 52W low
0.0%
$0.68
$4.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores BioNexus Gene Lab Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
16/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Volatility
37
Issuance
30
Growth
29
Quality
25
Revisions
20
Value
7
Momentum
3

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BGLC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BGLC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26BGLC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BGLC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BGLC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, BioNexus Gene Lab Corp. returned −85.8% against +9.2% for the S&P 500, dividends included.

BGLC vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26BGLCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BGLC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.6×

Cheaper than 75% of US stocks

Price / book
0.2×

Cheaper than 94% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−96.6%

Higher than 2% of US stocks

Earnings growth (YoY)
—
Gross margin
17.0%

Higher than 17% of US stocks

Operating margin
−88.2%

Higher than 15% of US stocks

Net margin
−82.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−33.7%

Higher than 27% of US stocks

Return on assets
−19.0%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioNexus Gene Lab Corp. has a market value of $2.0M.

  • Revenue in the twelve months to 30 June 2026: $3.1M. The latest quarter shrank 96.6% year on year.

  • Net income over the same four quarters: −$2.6M, a −82.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$854K.

  • Shares outstanding: 2.4M.

  • BioNexus Gene Lab Corp. employs 19 people — $165K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BGLC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
BGLCBioNexus Gene Lab Corp.$2.0M16
CNEYCN Energy Group, Inc.$3.0M18
YMATJ-Star Holding Co., Ltd.$3.5M2
SNESSenesTech, Inc.$4.7M33
BONBon Natural Life Ltd.$8.5M18
LOOPLoop Industries, Inc.$11.6M15
CITRCitroTech, Inc.$52.2M44

Take a look at BGLC’s peer groups, ranked by the model: industrial stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own BioNexus Gene Lab Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BGLC

How does Ticker Nerd's model rank BGLC?

As at 21 Nov 2026, BioNexus Gene Lab Corp. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

What is the BGLC stock forecast for 2030?

No analyst covering BioNexus Gene Lab Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BGLC are extrapolating price history, which says nothing about the business.

How has BGLC stock performed over the past year?

BioNexus Gene Lab Corp. returned -85.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioNexus Gene Lab Corp. do?

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services.

Company

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services. Through its subsidiaries, it supplies chemical raw materials used in industrial, medical, appliance, automotive, mechanical, and electronic manufacturing across Southeast Asia. BioNexus Gene Lab Corp. also develops blood-based diagnostic services that apply functional genomics and RNA analysis to support early disease detection and personalized health management. Its business model combines distribution of specialty materials with laboratory-focused healthcare solutions, positioning the company at the intersection of industrial supply chains and precision diagnostics. This mix gives BioNexus Gene Lab Corp. a role in both regional manufacturing markets and emerging molecular testing services.

CEO Mr. Su-Leng Tan · 19 employees · Malaysia · https://www.bionexusgenelab.com